When Clomid Stops Working: The 3 to 6 Cycle Rule

You are reading this on cycle three, or four, or five of clomid. You have probably ovulated on most of those cycles. The test was still negative. Or you ovulated on the first cycle but not the second, and your last scan showed nothing growing. The question you are sitting with is whether to push another cycle of clomid or change the plan, and the data is clearer than most patients realize.

I will not re-explain how clomid works, because you have lived inside that mechanism for several cycles already. What this post covers is the decision logic for what happens next: the signs that clomid is working for you, the signs it is not, what clomid resistance actually means, and the conversation worth having with your reproductive endocrinologist (RE) at the next appointment. I will not pretend this is a small conversation. By cycle four, it usually is not.

The 3 to 6 cycle rule

Here is the single most useful number in this entire post. Approximately seventy-five percent of clomid pregnancies happen within the first three ovulatory cycles.², ⁵ By the end of cycle six, the cumulative pregnancy rate plateaus. After that, additional clomid cycles add very little, and you are trading time, side effects, and emotional bandwidth for a diminishing return.

The American Society for Reproductive Medicine recommends discontinuing clomid after three to six ovulatory cycles without pregnancy.¹ That is not a hard rule, and your RE may extend it in specific scenarios (for example, a known prior responder back trying for a second baby, or a logistical constraint that makes IUI impractical in the short term). It is, however, the practice standard, and it exists because the per-cycle gain after the third or fourth ovulatory cycle gets small enough to no longer justify the cost of the cycle.

The framing I use with patients is this: clomid that has produced ovulation in three cycles without pregnancy is doing what the drug can do. It is no longer the limiting step. Continuing for cycles five and six is sometimes the right answer, but it is rarely a higher-yield move than changing protocol.

Signs clomid is working, for you

"Working" is a slippery word in this conversation, and worth being precise about. There are two things clomid can do, and they are not the same:

1. Produce ovulation: a follicle grows, ovulation happens, the corpus luteum forms, progesterone rises in the luteal phase.
2. Produce a pregnancy: sperm meets egg in time, the embryo implants, the lining accepts it.

Clomid only controls the first of those. The second depends on tubes, sperm, lining, and timing.

You can tell clomid is doing the first job for you by checking three things:

• Confirmed ovulation: either a positive luteinizing hormone (LH) surge on an ovulation predictor kit (OPK), a follicle of 18 to 22mm seen on the monitoring scan, or a progesterone level above 10 ng/mL seven days post-ovulation. Any one of those is reasonable evidence; two or three is firm.
• Adequate lining on trigger day: seven millimeters or thicker, with a trilaminar appearance.
• A reasonably predictable cycle length: variation of a few days is normal. Wild variation across cycles suggests the response is inconsistent.

If all three are true and you have completed three ovulatory cycles without pregnancy, the cleanest interpretation is that clomid is working pharmacologically and the limit on pregnancy is somewhere else. Your RE will start looking at tubes, sperm, lining quality, and timing.

Signs clomid is not working

The other failure mode is that the drug is not producing ovulation, or is producing it inconsistently. The patterns to watch for:

• No ovulation despite maximum dose: if 150mg has been tried and no follicle is recruiting, the formal label is clomiphene-resistant PCOS, which affects approximately fifteen to twenty percent of people with PCOS taking clomid.⁴
• Lining persistently below 7mm: even when a follicle grows, a thin lining limits the cycle's chance. Roughly fifteen percent of clomid cycles show this on monitoring.²
• Cycles getting longer rather than shorter: late or absent ovulation across consecutive cycles suggests the ovary is not responding crisply to the FSH push.
• Cycle cancellation for inadequate response: if your team has cancelled a cycle for not enough follicular development, that is meaningful data.

These are the situations where the question stops being "another cycle of clomid" and starts being "what is the next step."

What clomid resistance actually means

Clomiphene resistance is not the drug failing to act in your body. The receptor blockade still occurs. What is failing is the ovary's response to the resulting FSH pulse. The hypothalamus and pituitary are doing what they are supposed to do; the follicle is not crossing the selection threshold.

The features that predict clomid resistance are mostly the features of more severe PCOS: higher body mass index, higher anti-Mullerian hormone (AMH), more severe insulin resistance, longer baseline cycles, and higher free androgen index. The Imani prediction model from the late 1990s formalized some of these factors, and the broad pattern has held up in subsequent cohorts.³, ⁵

Two practical responses to clomid resistance exist. The first is to add metformin to the next cycle of clomid, which improves ovulation rates in a subset of insulin-resistant patients. The second, and more common in current practice, is to switch to letrozole. Several trials and the 2018 Cochrane review show that letrozole rescues ovulation in a meaningful proportion of clomid-resistant PCOS patients.⁴ The 2023 International PCOS Guideline endorses letrozole as first-line for PCOS specifically because the response profile is better, including in clomid-resistant cases.⁶

The third option, which your RE may raise depending on your age and history, is to step up entirely, either to gonadotropin injections with intrauterine insemination (IUI) or to in vitro fertilization (IVF). That conversation usually depends on age, ovarian reserve, partner sperm parameters, and how much time you have.

The harder scenario: ovulating but not conceiving

This is the scenario I see most often in cycle three or four. The scans look fine. Ovulation is documented. Progesterone is in range. The test is still negative.

When clomid is producing reliable ovulation but pregnancy is not happening, the diagnostic question shifts. The drug is no longer the variable. The next set of questions is:

• Tubes: Has a hysterosalpingogram (HSG) been done? Both tubes patent?
• Sperm: Has a semen analysis been done in the last six months? Are parameters in the WHO normal range?
• Lining: What has the trigger-day lining been across the cycles? If it has been less than 7mm, the drug is the limit.
• Timing: Has the trigger and intercourse timing been precise enough? Some couples are missing the window by twelve to twenty-four hours.
• Age and ovarian reserve: If you are over 35, the time-cost of additional unmonitored cycles is real.

The pivot most patients face at this point is between two options. Option one is to add IUI to the existing clomid cycle, which addresses timing and partly addresses borderline sperm, while keeping the drug constant. Option two is to switch drug to letrozole, with or without IUI, which addresses lining and gives the cycle a different shape. Many REs combine both moves: switch to letrozole and add IUI in the next cycle, particularly if you have done three ovulatory clomid cycles already.

The lining problem, specifically

Approximately fifteen percent of clomid cycles end with a lining below 7mm on trigger day.² If your monitoring scans across the last few cycles have shown this pattern, the drug is the limiting factor and switching to letrozole is the cleanest move. Lining typically rebounds within a single cycle of switching, because letrozole clears the body before the lining is fully exposed to rising estrogen.

I want to flag this specifically because it is the cycle issue most patients are not told about explicitly. The scan happens, the lining number is recorded, the cycle proceeds with intercourse or IUI, and the negative test follows. The lining number was the early warning, and it does not get raised at the post-cycle debrief unless a patient asks. If you are on cycle three and you have not seen your trigger-day lining numbers across cycles, that is worth asking about at the next visit.

The decision tree your RE may walk through

A rough version of how I think through cycle three or four logic, before sitting down with the patient:

1. Are you ovulating? If no on maximum dose, the next move is letrozole or, in some cases, letrozole plus metformin.
2. Is the lining adequate? If consistently less than 7mm, switch to letrozole.
3. Is the sperm adequate? If borderline, add IUI in the next cycle regardless of drug choice.
4. Are the tubes confirmed patent? If not, HSG before the next cycle.
5. What is age and ovarian reserve? If under 35 with normal AMH, time is on your side and continuing oral cycles is reasonable. If over 38 or AMH low, the conversation usually accelerates toward IUI or IVF.

Most cycle-three decisions end up in one of four buckets: switch drug, add IUI, do both, or step up entirely. Continuing the same protocol unchanged is the bucket I most rarely recommend.

The conversation to have at the next appointment

When you go in for the post-cycle debrief, the questions worth asking, in order:

• "What does my cycle data look like across these cycles?" Ask for the specific numbers: follicle sizes, lining thickness, progesterone, any cancelled cycles. If your team has not laid this out for you side by side, it is worth asking them to.
• "Are we changing dose, changing drug, or adding IUI?" This is the real branching question. Force the choice into the open.
• "Should I be on metformin?" If you have insulin resistance markers or a higher BMI and have not been offered metformin, ask.
• "When would you recommend stepping up to gonadotropins or IVF?" Even if the answer is "not yet," knowing the threshold ahead of time makes the next decision easier.
• "What is the cancellation criterion if too many follicles develop on a different drug?" This is the safety question for the next cycle.

If you have a partner involved in this, bring them. Cycle three and four decisions are easier to think through with a second person who has watched the same cycles.

What's next

• If your RE has just recommended switching drugs: switching from clomid to letrozole, what changes
• If you are deciding between continuing clomid and adding IUI: moving up to IUI
• If you want a refresher on the underlying drug comparison: clomid vs letrozole, which one and why
• If the issue is metformin rather than clomid itself: metformin and letrozole, the combination
• If this cycle failed and you need support before the next decision: when things don't go to plan

Related in this cluster

• Clomid: How It Works and Why It's Used Less for PCOS Now

Sources

1. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertility and Sterility 2013;100(2):341-348. https://www.asrm.org/practice-guidance/practice-committee-documents/
2. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2016;(12):CD002249. https://doi.org/10.1002/14651858.CD002249.pub5
3. Imani B, Eijkemans MJC, te Velde ER, Habbema JDF, Fauser BCJM. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Journal of Clinical Endocrinology & Metabolism 1998;83(7):2361-2365. https://doi.org/10.1210/jcem.83.7.4948
4. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2014;371(2):119-129. https://www.nejm.org/doi/full/10.1056/NEJMoa1313517
5. Eijkemans MJC, Imani B, Mulders AGMGJ, Habbema JDF, Fauser BCJM. High singleton live birth rate following classical ovulation induction in normogonadotropic anovulatory infertility (WHO 2). Human Reproduction 2003;18(11):2357-2362. https://doi.org/10.1093/humrep/deg459
6. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025